Lexeo Therapeutics (LXEO) Capital Leases (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Capital Leases data on file, last reported at $198000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases fell 71.63% year-over-year to $198000.0; the trailing twelve-month figure through Mar 2026 stood at $198000.0 (down 71.63% YoY), and the FY2025 full-year result was $327000.0, down 59.98% from the prior year.
• Capital Leases slipped to $198000.0 in Q1 2026, from $327000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $1.6 million in Q4 2022 to a low of $198000.0 in Q1 2026.
• A 5-year average of $870333.3 and a median of $873500.0 in 2024 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases retreated 24.33% in 2023 and plunged 71.63% in 2026, its largest moves.
• Tracing LXEO's Capital Leases over 5 years: stood at $1.6 million in 2022, then retreated by 24.33% to $1.2 million in 2023, then sank by 34.48% to $817000.0 in 2024, then sank by 59.98% to $327000.0 in 2025, then tumbled by 39.45% to $198000.0 in 2026.
• Business Quant data shows LXEO's Capital Leases at $198000.0 in Q1 2026, $327000.0 in Q4 2025, and $454000.0 in Q3 2025.